Market News AIOpen the app

AARD stock news · Aardvark Therapeutics

Stories about Aardvark Therapeutics (AARD) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for AARD

Follow Aardvark Therapeutics (AARD) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AARD
Free on the App Store and Google Play, or on the web.
  1. Oct 23, 2026, 1:24 PM ET · Market

    12 health care companies are seeing big changes in their stock prices today.

    Neutral

    Aardvark Therapeutics’ share price fell about 57% during Friday’s session, but the article gives no business reason for the drop. It adds no new information about the company’s outlook.

  2. Oct 23, 2026, 11:50 AM ET · Market

    Aardvark Therapeutics says the information about its Prader-Willi Syndrome drug isn't enough.

    Bad for AARD

    Aardvark's early trial data showed modest, fading hunger relief, despite improvement in an extension group. The results leave the drug's benefit unproven, making the news unfavorable for AARD.

  3. Oct 23, 2026, 8:20 AM ET · Market

    12 health care companies are changing a lot in Friday's early trading.

    Neutral

    Aardvark Therapeutics' shares fell about 11% to $3.52 in Friday's pre-market session. The report gives no company update, so the move alone does not change Aardvark Therapeutics' business outlook.

  4. Oct 8, 2026, 4:20 PM ET · Market

    Aardvark Therapeutics has new board members and has hired some new officers.

    Neutral

    Aardvark added a director with biotech trial and regulatory experience. The filing reports no change to the company’s plans or results, so the appointment alone does not change its outlook.